Michael J. Ross, Ph.D.
General Partner, SV Life Sciences

Dr. Michael Ross joined SVLS as a Venture Partner in 2001 and became a General Partner in 2002. Dr. Ross serves on the boards of Archemix, Glycofi, Rinat and the Thayer School of Engineering (Dartmouth College). He has also served on the boards of Aderis Pharmaceuticals, Arris Pharmaceutical, Carta Proteomics, CyThera, Epimmune, Genencor, MetaXen and Xenova. Dr. Ross was the tenth employee at Genentech where he worked for 13 years. He served as Genentech team leader for Humulin® (human insulin-Lilly), Roferon® (Interferon alpha -Roche), Protropin® (hGH), and was Vice President of Development during the development of Activase®, Nutropin® and Pulmozyme®. Dr. Ross then started Genentech's protein engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. Dr. Ross was the Founding CEO of Arris Pharmaceutical, (now part of Celera), MetaXen, (now part of Exelixis), ExSAR and CyThera (now part of Novocell). Dr. Ross was most recently Managing Partner in Didyma, LLC, a biotechnology management consulting firm. Dr. Ross received his AB from Dartmouth College, his PhD in Chemistry at Caltech, and completed a Post Doctorate in Molecular Biology at Harvard.